Recombinant Zoster Vaccine Cost-Effective in Simulation

TUESDAY, Feb. 19, 2019 -- Vaccination with recombinant zoster vaccine (RZV) seems cost-effective under a wide range of conditions, according to a study published online Feb. 19 in the Annals of Internal Medicine. Lisa A. Prosser, Ph.D., from the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news